Literature DB >> 2525877

Cardiac performance after reduction of myocardial hypertrophy.

R E Schmieder1, F H Messerli, D Sturgill, G E Garavaglia, B D Nunez.   

Abstract

PURPOSE: The current study was performed to assess the functional sequelae of reducing left ventricular hypertrophy in patients with essential hypertension. PATIENTS AND METHODS: To analyze left ventricular function and contractility in patients with essential hypertension after reduction of left ventricular hypertrophy, 14 patients with essential hypertension and left ventricular hypertrophy were studied prospectively by echocardiogram (1) before, (2) during, and (3) after left ventricular mass had been reduced by antihypertensive therapy of 19 +/- 3 months' duration. All drugs were discontinued four weeks before the first and the third study.
RESULTS: At the time of the third study, arterial pressure had returned to pretreatment values, and mean, peak, and isovolumetric (but not end-systolic) wall stress increased, whereas left ventricular mass remained diminished. Despite the increased pressure load to the heart, myocardial contractility was maintained or improved after reduction of left ventricular hypertrophy, as indicated by the ratio of end-systolic wall stress to end-systolic volume index (p less than 0.02) and by the relation of fractional shortening to end-systolic wall stress (p less than 0.06). End-diastolic volume, an indicator of preload, remained reduced after therapy (p less than 0.05). As a result, pump function of the left ventricle improved as shown by an increase in the ejection fraction (p less than 0.05), fractional fiber shortening (p less than 0.05), and velocity of circumferential fiber shortening (p less than 0.01).
CONCLUSION: Thus, in patients with essential hypertension, reduction of myocardial hypertrophy by antihypertensive therapy appears to be beneficial rather than detrimental to cardiac pump performance.

Entities:  

Mesh:

Year:  1989        PMID: 2525877     DOI: 10.1016/s0002-9343(89)80478-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Risks versus benefits of withdrawing antihypertensive therapy.

Authors:  H P Schobel; R E Schmieder; F H Messerli
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

Review 2.  Regression of increased left ventricular mass by antihypertensives.

Authors:  C J Lavie; H O Ventura; F H Messerli
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Impact of left ventricular geometry on prognosis-a review of ochsner studies.

Authors:  Carl J Lavie; Richard V Milani; Sangeeta B Shah; Yvonne E Gilliland; Jose A Bernal; Homeyar Dinshaw; Hector O Ventura
Journal:  Ochsner J       Date:  2008

Review 4.  Role of ACE inhibitors in hypertension with left ventricular hypertrophy.

Authors:  A M Richards; M G Nicholls; I G Crozier
Journal:  Br Heart J       Date:  1994-09

Review 5.  Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy.

Authors:  P R Liebson; R D Serry
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

6.  Left ventricular hypertrophy is independently associated with all-cause mortality.

Authors:  Mohammad Reza Movahed; Radhakrishnan Ramaraj; Coraly Manrique; Mehrnoosh Hashemzadeh
Journal:  Am J Cardiovasc Dis       Date:  2022-02-15

Review 7.  Hypertension and age-related changes in the heart. Implications for drug therapy.

Authors:  S Isoyama
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

Review 8.  Risk and management of hypertension-related left ventricular hypertrophy.

Authors:  K K Teo
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

9.  Left Ventricular Hypertrophy.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-10

10.  Effects of Different Systolic Blood Pressure Targets on Myocardial Function: A One-Year Follow-Up in Geriatric Hypertension.

Authors:  Xiaoyan Chen; Qingmei Yang; Jianxiu Fang; Haifeng Guo
Journal:  Int J Gen Med       Date:  2021-07-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.